Compounds of formula (la) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, -C1-Cealkyl, -C1-Ceaminoalkyl, -C1-C6hydroxyalkyl, -haloC1-C6alkyl, -C1- C6alkoxyl, -haloC1-C
公式(la)的化合物及其药学上可接受的盐、溶剂化合物和水合物,以及相关的调节细胞上穿孔素活性的方法:其中环A选自6-10成员芳基、5-6成员环烷基、5-6成员杂芳基或5-6成员杂环烷基,其中杂芳基和杂环烷基环至少包含N、O或S中的一种杂原子;芳基、环烷基、杂芳基或杂环烷基环可以选择地被1至3个取代基取代,所述取代基选自卤素、硝基、-C1-Ce烷基、-C1-Ceamino烷基、-C1-C6羟基烷基、-卤代C1-C6烷基、-C1-C6烷氧基、-卤代C1-C6烷氧基、杂芳基、芳基、羟基、-C(0)Ci-C6烷基、-OC(0)Ci-C6烷基、-CH2OC(O)CrC6烷基、-C(O)OC1,-C6烷基、-NHC(O)C1,-C6烷基、-NHS(O)2C1-C6烷基、-S(O)2C1-C6烷基、-S(O)2NH2和-C(O)NJJ;环B是6-10成员芳基或5-6成员杂芳基,其中至少包含N、O或S中的一种杂原子;芳基或杂芳基可以选择地被一个或多个取代基取代,所述取代基选自-NJJ、-OJ、卤素、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基和-C(0)NJJ;环C选自5-10成员杂芳基或5-10成员杂环烯,每个环至少包含N、S和O中的一种杂原子;环D是可选择地取代的苯并9-11成员杂环烷基或可选择地取代的苯并9-11成员杂芳基,其中至少包含N或O中的一种杂原子;L是从支链和非支链C1-C4烷基、-S(0)2-NH-、-C(0)-NH-、-NH-C(0)-NH-、-S(0)2-NH-C(0)-NH-、-S(0)2-NH-C(0) -和-CH=CH-中选取的连接物;其中环B和C,以及环C和D,通过各自环上任何可用的C原子之一的C-C键连接在一起;每次出现的J独立地选自H、可选择地取代的C1-C6烷基或可选择地取代的卤代C1-C6烷基。
[EN] PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DES PGE2
申请人:IDORSIA PHARMACEUTICALS LTD
公开号:WO2018210988A1
公开(公告)日:2018-11-22
The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
本发明涉及式(I)的嘧啶衍生物,其中(R1)n,R3,R4a,R4b,R5a,R5b和Ar1如描述中所述,以及它们通过调节免疫反应,包括肿瘤中免疫系统的再激活,用于治疗癌症。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(II),及其作为药物的使用,其制备,药用可接受的盐,及其作为药物的使用,以及包含式(I)中一个或多个化合物的药物组合物,尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
[EN] BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE BENZOFURANE ET DE BENZOTHIOPHÈNE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR PGE2
申请人:IDORSIA PHARMACEUTICALS LTD
公开号:WO2018210987A1
公开(公告)日:2018-11-22
The present invention relates to benzofurane and benzothiophene derivatives of formula (I) Formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
本发明涉及公式(I)的苯并呋喃和苯并噻吩衍生物,其中(R1)n,R2,R3,R4a,R4b,R5a,R5b和Ar1如描述中所述,并且它们在通过调节免疫应答包括在肿瘤中重新激活免疫系统的治疗中的用途。该发明还涉及公式(II)的新型苯并呋喃和苯并噻吩衍生物及其作为药物的用途,其制备,其药学上可接受的盐,以及其作为药物的用途,含有一个或多个公式(I)化合物的药物组合物,特别是它们作为前列腺素2受体EP2和/或EP4的调节剂的用途。